Table Of Content

AUTHOR INDEX Alito, K. 69 Ledoux, D. 107 Armstrong, I 69 Lemoine, N. R Aste-Amezaga, M 55 Linsley, P.S. 15 Logan, A. 45 Balkwill, F. R. 121 Barritault, D. 10 Maini, R. N Berg, D. 207 Martin, P. 25 Border, W. A McCluskey, J Brennan, F.M. 2 Metz, C. N Bruce, A. G 5 CChaeirrhppieemnntie,tr ,e rJ,. GG. 3 559 7 NNio. ebllsee,n , N. A.F. C. 33 26597 Cope, A. P. 247 Partanen, J. 69 D'Andrea, A. 355 Prigent,S. A. 1 Feldmann, M. 2 Rengaraju, M Rennick, D Rifkin, D. B Gannoun-Zaki, Rose, T. M Gibbons, D. I Siddle, K 301 Harpel, J.G. 321 Harper, J. R. 369 Hill, D. J. 45 Takiguchi, Y. 191 Holland, G. 207 Thatcher, N. 229 Hopkinson-Woolley, J lrinchieri, G. 355 Ip, N.Y. 139 Vainikka, S. 69 Valiante, N. M Van Vlasselaer, P Jones, G. 97 von Rohr, A. 229 Katsikis, P.D. 2 Williams, R. O. 247 Kawashima, | Wysocka, M. 35 Kojima, S Korhonen, J Kubin, M 5 Yancopoulos,G. D. 139 UBJECT INDEX Activin A and B, embryonic skeletal anti-tumour action in animal models 126 development 48 cachexia in animal models 128 Acute phase proteins, induction by oncostatin clinical trials in humans 129 M 162 enhancement of tumour spread in animal Adipogenesis, regulation by interleukin-11 200 models 128 Adipogenesis inhibitory factor (AGIF) 192 production by human ovarian cancer 130 molecular cloning of cDNA 193 type | growth factor receptors 1-24 AIDS patients, NKSF/IL-12 365 ‘artilage growth plate 45, 46, 50 AIDS-related Kaposi's sarcoma cells, effect of ell-mediated immunity 207 oncostatinM 161 interleukin-10 212, 221 Amphiregulin, role in cancer 9 erbB-2 proto-oncogene 4, 13 Amyotrophic lateral sclerosis, CNTF 141, 148 -erbB-2 receptor, potential ligands Angiogenesis, TNF 124 erbB-3 proto-oncogene 6, 13 Angiogenic factors, FGF and wound hemoimmunotherapy 241 healing 31 hemotherapeutic agents, interleukin-2 Antigen presenting cells, interleukin-10 210 combination in treatment of malignant Anti-inflammatory agent, interleukin-10 215 tumours 239 Arthritis holinergic neuronal differentiation factor 338 cytokine system 249 hondrocalcinosis 61 growth factors 61 ‘hondrocytes 45, 50, 56 LIF 347 ‘hondrogenesis 46-68 INFa 125, 353 ‘iliary neurotrophic factor (CNTF) 139, 157 Autoimmune disease, TNFa in rheumatoid biological actions 140 arthritis 247-2=5 5 gene structure 162 molecular cloning of binding protein 141 receptor 165 B cells distribution and CNTF targets during NKSF/IL-12 production 356 development 148 stimulation by interleukin-10 211, 219 roles 150 Beckwith-Wiedeman syndrome, IGF-II 267 signal transduction 142 Bibliographic update structure 142, 358 growth inhibitors 291-300 role during embryogenesis and as a insulin-like growth factor 171-190, 383-39 muscle-derived factor 149 platelet-derived growth factor 85-96 role in injury 149 Biglycan, TGF-B interaction 377 isplatin, interleukin-2 combination Bone treatment 241 growth factors and embryonic ollagen, IGFs 57 development 46 ‘ollagen induced arthritis LIF 337-353 cytokine system 247 Bone marrow 191 INFa 253 adipogenesis 193, 200 ‘onnective-tissue wound contraction 26, 34 interleukin-10 and hemopoiesis 217, 219 ‘ripto 12 interleukin-11 and hemopoiesis 196, 19 yclophosphamide, interleukin-2 combination Bone marrow regeneration treatment 241 interleukin-10 220 ytokine inhibitors 252 LIF 346 ‘ytokine receptors 122, 142 Bone morphometric proteins-2B and 3 49 ytokine synthesis inhibitory factor (CSIF) 208, 210 Brain-derived neurotrophic factor 139, 140 Breast cancer c-erbB-2 5, 13 FGF receptor genes Decarbazine, interleukin-2 combination treatment 241 Decorin 373 Cachexia, TNI 128 in vivo effects 380 Cancer in vivo pharmacokinetics TNF 125 TGF-8 interaction 377 SUBJECT INDEX Development, IGF-II 263, 27 5 Glomerulonephritis Differentiation-inhibitory activity 338 decorin pharmacokinetics Doxorubicin, impaired wound healing, TGF-B 370, 374 TGF-B 36 gp 130 144, 147, 164 G proteins, phospholipase C regulation 103 Granulocyte colony-stimulating factor 142, 157 gene structure 162 smbryo receptor 165 growth factors and skeletal development 4 Growth factor receptors, type 1, involvement IGF-II and receptors 277, 280 in cancer 1-24 2mbryonic stem cells, effect of oncostatin Growth hormone 162 M 161 IGF-1 interaction 55 =pidermal growth factor (EGF) receptors 165 structure and functions, cancer Growth inhibitors, bibliographic tyrosine phosphorylation of phospholipase update 291-300 C 100 Growth promoting agent (GPA) 149 wound healing 28 :pidermal growth factor receptors and ligands role in cancer 1-24 Haemorrhagic necrosis, TNF 127, 129 :rythroid progenitors Hematopoietins 158, 164 interleukin-10 217 Hemopoiesis 191 interleukin-11 197 interleukin-10 216, 219 =xtracellular matrix, TGF-£ interaction interleukin-11 197 329, 370, 372 Heparan sulfate, FGF receptor binding 110 decorin pharmacokinetics Heparin, FGF interaction 70 integrin expression 375 Heparin-binding epidermal growth factor protease activity 374 (HB-EGF) proteoglycan interactions cancer 10 wound healing 28 Hepatic cells, effect of oncostatin M 162 Hepatocyte stimulatory factor III 338 Fetus, skeletal development and HER-2 4 chondrogenesis 46 Heregulin 7, 12 Fibroblast growth factors (FGFs) HIV+ patients, NKSF/IL-12 365 cellular localisation 113 Horton’s arthritis, LIF 347 chondrocyte replication 56, 59 Huntington's disease, FGF receptor genes 79 disease and repair of articular cartilage 61 Hybrid receptor, IR/IGFR 301, 312 embryonic skeletal development 47 epiphyseal growth plate 52 responses in various cells 70 Immunity 207 tyrosine phosphorylation of phospholipase HIV infection, NKSF/IL-12 Cc 100 interleukin-10 210, 212, 216 wound healing 30 Immunotherapy, interleukin-2 229, 241 Fibroblast growth factor gene family 69 Impaired wound healing, TGF-8 36 Fibroblast growth factor receptors Infectious disease, TNF 125 biochemical characterisation 70, 107 Inflammation cell distribution 107 interleukin-10 213 collaboration of high and low affinity macrophages and growth factors 26 receptors in FGF oncostatin M 162 binding 75 Inflammatory joint disease 61 expression 76 INF 125 genomic localisation of genes and Insulin, collagen synthesis 58 involvement in disease 79 Insulin dependent diabetes mellitus 247, 248 internalisation 112, 113 Insulin-like growth factor (IGF), bibliographic ligand binding 74 update 171-190, 383-397 molecular cloning 71 Insulin-like growth factor I signal transduction 70, 7 chondrocyte replication 57, 59 subtypes 73 disease and repair of articular cartilage 61 tissue distribution and mRNAs_ 109 embryonic skeletal development 48 Fibroblasts epiphyseal growth plate 54 effect of oncostatin M 162 growth hormone interaction 55 wound healing 27 Insulin-like growth factor I receptor 270, 301 Fibronectin, TGF-B interaction activation and tyrosine kinase 307 Fibrotic disease, TGF-B 370 gene structure and function 303 SUBJECT INDEX intracellular signalling 308 regulation of adipogenesis 200 ligand binding 305 regulation of antigen-specific antibody signalling specificity 311 responses 199 structure 03 regulation of hepatic acute-phase subtypes 312 responses 200 Insulin-like growth factor II therapeutic potential 202 binding proteins 276 Interleukin-12 biological actions 279 HIV seropositive and AIDS patients biosynthesis 261 responses ba) cellular mechanism of action 280 lymphocyte-mediated cytotoxicity 360 chondrocyte replication 57, 59 lymphokine production 359 developmental regulation 277 molecular structure and receptors embryonic skeletal development 48 physiological roles 362 epiphyseal growth plate 54 production 361 gene expression 262 ) regulation of T and NK cell structure 59 proliferation 360 tissue distribution tumours 267 Insulin-like growth factor II receptor 269 Kaposi's sarcoma cells, effect of oncostatin 79 «O77 M 161 Insulin receptor (IR) 301 Keratinocyte autocrine factor (KAF) 10 activation and tyrosine kinase 30 Keratinocyte growth factor (KGF) gene structure and function 303 embryonic skeletal development intracellular signalling 308 wound healing 31 ligand binding 305 Keratinocyte growth factor receptor signalling specificity Kidney disease, TGF-B 370 structure 303 subtypes 312 Insulin receptor-related receptor (IRR) amellipodial crawling 26 INT-2, embryonic skeletal development atency associated peptide, TGFa Integrin, TGF-B and expression of 375 eukemia cells, oncostatin M_ 160 a-Interferon, interleukin-2 combination in eukemia inhibitory factor (LIF) treatment of malignant tumours 237 - 38 150, 157, 161, 338 Interferon-B, induction of production by action on bone in vitro 339 NKSF/IL-12 359, 362, 365 action on bone in vivo 343 Interleukin-2, clinical applications bone disorders in humans 347 combination with chemotherapeutic pathological effects 344 agents 239 specific effects 346 combination with LAK cells 233 chromosomal localisation 164 combination with other cytokines gene structure 162 immunomodulators or monoclonal receptor 165 antibodies 237 Lymphokine, induction by NKSF/IL-12 combination with TIL Lymphokine-activated killer (LAK) cells single agent treatment interleukin-2 combination in treatment of Interleukin-6 145, 157 malignant tumours 229, 233, 241 gene structure 162 NKSP/II 12 induced generation 360 receptor 165 358 Lymphopoiesis, interleukin-10 218 Interleukin-10 Lymphotoxin 122 antigen presenting cells 210 B cell stimulation 211 bone marrow regeneration 220 a2-Macroglobulin, TGF-8 complex 324 cell-mediated immunity 212 Macrophages hemopoiesis 216 interleukin-10 inhibits cytokine molecular characterisation 208 production 215 therapeutic use 221 wound repair 26, 33 Interleukin-11 Malignant melanoma, interleukin-2 in early hematopoietic progenitors treatment 231, > 233, 237, 240 erythroid progenitors 197 Mannose 6-phosphate receptor, IGF-II gene 163, 194 76 277, 280 megakaryocyte progenitors 195 Mast cells, interleukin-10 and development molecular cloning of cDNA 193 of 218 myeloma cells 195 Megakaryocytes protein structure 194 interleukin-10 217 receptor and signal transduction 164 interleukin-11 195 SUBJECT INDEX Melanoma-derived lipoprotein lipase tyrosine phosphorylation of phospholipase inhibitor 338 C100 Motor neuron disease, CNTF 141, 148 wound healing a Mucopolysaccharides, IGFs and synthesis Profilin 2 of 57 Proteoglycans Myeloma cells FGF binding 70 interleukin-10 217 I'GF-B interactions interleukin-11 195 Myofibroblasts 27 ras p21, IR and IGFR = 309, 310 Renal cell carcinoma, interleukin-2 Natural killer cells treatment 231, 234, 240, 241 interleukin-10 210 Rheumatoid arthritis NKSF/IL-12 360 cytokine inhibitors 252 Natural killer cell stimulatory factor (NKSF) cytokine system 249 HIV seropositive and AIDS patients growth factors 61 responses 365 LIF 347 lymphocyte-mediated cytotoxicity 360 INFa 125, 253 lymphokine production 359 molecular structure and receptors 356 physiological roles 362 Scar tissue formation 27, 37 production 361 Schwann cells, CNTF 149 regulation of T and NK cell Schwannoma-derived growth factor proliferation 360 SH2 domains 308 Nerve growth factor 139 Signal transduction Nerve injury, CNTF 149, 150 CNTF 142 Neuro-activating factor (NAF) 13 EGFR abnormalities Neurotrophic factors 139 FGF receptors 70 interleukin-11 201 oncostatinM 166 Oncogene Skeletal development 46 c-erbB-2 4, 13 Skin, growth factors and wound c-erbB-3 6 healing 25-44, 374 Oncostatin M (OSM) 157 Stem cells, interleukin-10 216 gene structure 158 Stromal cells 191 in vitro effects 160 interleukin-10 219 protein structure 158 interleukin-11 192, 200 receptors 164 relationship with other cytokines 162 signal transduction 166 r cells Osteoblasts, LIF 340 interleukin-10 210 Osteoclast-activating factor 8, NKSF/IL-12 360, 362 Osteoclasts, LIF 339 Thymocytes, interleukin-10 219 Osteogenin 49 Tissue repair Ovarian cancer, TNF production 130 TGF-a 34, Transforming growth factor-a (TGE cancer 8, 14 Parasites, interleukin-10 and cell-mediated wound healing 28 immunity 213 Transforming growth factor-B (TGI Peptide growth factors, chondrogenesis 45-68 activation 325 Phosphatidylinositol, receptor coupled chondrocyte replication 58 hydrolysis 98 decorin pharmacokinetics 379 Phosphatidylinositol 3-kinase, insulin and disease and repair of articular cartilage IGF 309 embryonic skeletal development 48 Phospholipase C isozymes 97 epiphyseal growth plate 55 cellular and subcellular localisation 99 extracellular matrix synthesis regulation by G proteins 103 integrin expression 375 regulation by serine phosphorylation 102 latency 322 regulation by tyrosine phosphorylation 99 a2-macroglobulin complex structure 98 physiological activity 369 Plasmacytoma cells, interleukin-11 195 protease activity 374 Plasmin, TGF-B 374 proteoglycan interactions Platelet-derived growth factor (PDGF) structure 322 bibliographic update 85-96 therapeutic interventions SUBJECT INDEX wound healing 34, 370 IR and IGFR 307 Tumour immunity, TNE 2 neurotrophins 140 Tumour-infiltrating lymphocytes, interleukin-2 phospholipase C regulation 99 combination in treatment of malignant tumours 236 Tumour necrosis factor (TNF) cancer 125 Vaccinia virus growth factor (VVGF) anti-tumour action in animal models 126 Vascular endothelium, TNF 124 cachexia in animal models 128 Viral growth factors 11 clinical trials in humans 129 enhancement of tumour spread in animal models 128 production by human ovarian cancer 130 Wilm’s tumour, IGF-II cell regulation 123 Wound healing 25 inflammatory, infectious and autoimmune EGFs 28 diseases 125 FGFs 30 inhibitors 252 impaired 36 production 122 macrophages 26 receptors 121, 252 myofibroblasts 27 rheumatoid arthritis 250-254 PDGF 32, 35 Tumours, IGF-II expression 267 scarring 27 Tyrosine kinase IGF-B 34 FGF receptors 70 tissue remodelling Printed and bound in Great Britain by BPC-AUP Aberdeen Ltd. = tore se